semaglutide news today october 2025 Novo Nordisk gears up for December Ozempic launch in India, sources say Semaglutide Market Size, Share &

Summary In summary, GLP-1 RA based therapies are being rigorously studied in management of MASLD in particular more advanced stages and likely will become foundational therapies in the future.

Immunoassays can be performed on a variety of standard clinical chemistry analyzers, thus ...

Oral semaglutide, therefore, represents an effective treatment option, that may lead to earlier initiation of GLP-1RA therapy in the diabetes treatment landscape.

GLP-1 medications like semaglutide and tirzepatide are changing the way we approach weight loss and type 2 diabetes

are former employees of Novo Nordisk.

I hope my friends in the compounding community call out this type of behavior and if I were one of the manufacturers of current approved GLP-1s (Novo Nordisk, Eli Lilly and Company, etc), I would explore legal action against any company who is blatantly abusing #drugshortage loopholes to engage in manufacturing and not #compounding